These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6801680)

  • 1. Hemophilia and hemostasis. Introductory remarks.
    Barker LF
    Prog Clin Biol Res; 1981; 72():xix-xxiii. PubMed ID: 6801680
    [No Abstract]   [Full Text] [Related]  

  • 2. Obtention production and use of factor VIII in Costa Rica.
    Cordero R; Montero C
    Scand J Haematol Suppl; 1984; 40():509-11. PubMed ID: 6433473
    [No Abstract]   [Full Text] [Related]  

  • 3. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia.
    Lange D; Lazerson J
    Wis Med J; 1982 Feb; 81(2):28-31. PubMed ID: 6803446
    [No Abstract]   [Full Text] [Related]  

  • 4. [Collection and utilization of plasma in Austria: on the way to national self-sufficiency].
    Bergmann H; Lukas M; Prusa P
    Beitr Infusionsther Transfusionsmed; 1996; 33():103-10. PubMed ID: 8974681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the donor can correct the nation's blood imbalance.
    Poppvsky MA
    Transfusion; 2006 Apr; 46(4):501-2. PubMed ID: 16584423
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma procurement world-wide.
    Leikola J
    Beitr Infusionsther; 1989; 24():69-73. PubMed ID: 2481551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safe blood components for a hemophilia patient: a case report.
    Chuansumrit A; Pandhawong S; Tardtong P; Isarangkura P
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():198-200. PubMed ID: 7886573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIII supply and demand.
    Jones P
    Br Med J; 1980 Jun; 280(6230):1531-2. PubMed ID: 6770954
    [No Abstract]   [Full Text] [Related]  

  • 9. Blood: a circular story.
    Steinbrook R
    Health PAC Bull; 1979; (81-82):11. PubMed ID: 10240885
    [No Abstract]   [Full Text] [Related]  

  • 10. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross.
    Eder AF; Herron R; Strupp A; Dy B; Notari EP; Chambers LA; Dodd RY; Benjamin RJ
    Transfusion; 2007 Apr; 47(4):599-607. PubMed ID: 17381617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophilia.
    Aledort LM
    N Engl J Med; 2001 Oct; 345(14):1066; author reply 1067. PubMed ID: 11586968
    [No Abstract]   [Full Text] [Related]  

  • 12. Can a national all voluntary blood transfusion service by adequate blood component therapy cover actual and future needs of albumin?
    Barker LF; Cazal P; Haussman HG; Hollán S; Kellner A; Lundsgaard-Hansen P; Schiff P
    Vox Sang; 1976; 31?-73(3):225-38. PubMed ID: 969394
    [No Abstract]   [Full Text] [Related]  

  • 13. Bad blood.
    Newman RJ; Podolsky D; Loeb P
    US News World Rep; 1994 Jun; 116(25):68-70, 72-8. PubMed ID: 10134824
    [No Abstract]   [Full Text] [Related]  

  • 14. [Production of factor VIII preparations and their use in the substitution therapy of hemophilia A].
    Gaerisch F; Stein P
    Z Gesamte Inn Med; 1982 Oct; 37(19):641-4. PubMed ID: 6817530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Transfusion medicine and blood donor services. The organization of the Blood Donor Service of the Swiss Red Cross].
    Bucher H
    Ther Umsch; 1984 Aug; 41(8):536-9. PubMed ID: 6495229
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter: Use of cryoprecipitate.
    Britten AF
    N Engl J Med; 1976 Aug; 295(8):451. PubMed ID: 934251
    [No Abstract]   [Full Text] [Related]  

  • 17. [Guidelines of the Blood Donor Service of the Swiss Red Cross for standardizing preserved blood and blood components].
    Ther Umsch; 1984 Aug; 41(8):588-94. PubMed ID: 6495238
    [No Abstract]   [Full Text] [Related]  

  • 18. [Introductory comments on Blood Donor Service of the Swiss Red Cross].
    VON ALBERTINI A
    Schweiz Med Wochenschr; 1953 Jan; 83(3):65-7. PubMed ID: 13056554
    [No Abstract]   [Full Text] [Related]  

  • 19. Variables that might affect the outcome of immune tolerance therapy in haemophiliacs with factor VIII inhibitors.
    Ehrenforth S; Kreuz W; Funk M; Auerswald G; Scharrer I
    Thromb Haemost; 1994 Nov; 72(5):784-5. PubMed ID: 7900088
    [No Abstract]   [Full Text] [Related]  

  • 20. [Percutaneous nephrolithotripsy supported by recombinant factor VIII in a patient with hemophilia A, a Jehovah's Witness].
    Azuno Y; Kaku K
    Rinsho Ketsueki; 1995 Dec; 36(12):1337-41. PubMed ID: 8587168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.